Genmab A/S GMAB.CO
Composite 52/100; the shares have moved about 33% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 15/100 — a strong mark against it.
Quality ranks 72/100 — a moderate point in its favour. Momentum ranks 67/100 — a moderate point in its favour. Balance-sheet strength ranks 55/100 — a slight point in its favour.
Valuation ranks 15/100 — a strong mark against it.
What the company does Genmab A/S discovers, develops, manufactures, and markets antibody-based therapies for cancer and other diseases. Its marketed products include EPKINLY, TEPKINLY, Tivdak, DARZALEX/DARZALEX FASPRO, RYBREVANT, TECVAYLI, TALVEY, Kesimpta, and TEPEZZA.
Key financials Revenue grew 25.3% while EPS fell 72.8%. Gross margin is 93.3% and net margin 21.1%. ROE is 15.0%, ROA 8.5%, and ROCE 11.9%. Debt/Equity is 0.94 and net debt/EBITDA 2.88.
Stock health Valuation metrics are elevated: P/E 22.12 (fwd 17.09), PEG 1.93, EV/EBITDA 16.86, P/B 3.14. SIDERAVIA scores Valuation at 25.6/100. Altman Z is 12.22, Piotroski F-Score 4/9.
Price vs fair value The stock trades at a PREMIUM of 56.00% versus our fair-value estimate and at a discount of 28.12% versus the analyst 12-month target. - Gross margin 93.3% and net margin 21.1% signal strong pricing power (company filings). - Analyst 12-month target 2392.08 implies 28.12% upside (analyst count 15.0). - Valuation percentile 25.6/100 indicates rich pricing relative to screened universe (SIDERAVIA). - Forward P/E 17.09 and PEG 0.58 suggest undemanding near-term earnings multiples (SIDERAVIA).
Looking forward Pipeline expansion into solid tumors and pediatric indications could extend growth runway. Execution risk remains around high-margin product uptake and margin sustainability.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.